+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 45Years +
All Genders
Healthy Volunteers
ID06330545

Study of Radiation Therapy to Prevent Recurrence of Dupuytrens Contracture After Collagenase Injection and Release

Led by Dartmouth-Hitchcock Medical Center · Updated on 2026-07-28

95

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying how to prevent the return of Dupuytrens Contracture, a condition affecting hand movement, after treatment with Collagenase Clostridium Histolyticum CCH. This phase II trial focuses on whether targeted radiation therapy can reduce the chance of contracture recurrence following a successful non-surgical release with CCH. Patients included are those with late or advanced stages of this condition. Participants will first receive CCH injection to release the contracture in the affected hand. After this, they will undergo two separate courses of radiation therapy, each lasting 5 days and separated by a rest period of 6 to 8 weeks. Following these treatments, participants will be observed for up to three years to monitor the recurrence of contracture and any treatment side effects. During the study, participants will have regular assessments to check for contracture recurrence defined by worsening finger movement and the presence of a palpable cord. Researchers will also monitor radiation-related side effects and gather patient-reported outcomes before, during, and after radiation treatment at multiple time points up to three years. The main outcome measured is contracture recurrence at several intervals after radiation therapy.

CONDITIONS

Brief Title

Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release

Research Team

P

Peter A DePalo, BS, CCRP

L

Lance Warhold, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here